These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 28017176)

  • 1. Levosimendan as a treatment for acute renal failure associated with cardiogenic shock after hip fracture.
    Hinojosa FQ; Revelo M; Salazar A; Maggi G; Schiraldi R; Brogly N; Gilsanz F
    Braz J Anesthesiol; 2017; 67(1):89-91. PubMed ID: 28017176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Levosimendan as a treatment for acute renal failure associated with cardiogenic shock after hip fracture].
    Hinojosa FQ; Revelo M; Salazar A; Maggi G; Schiraldi R; Brogly N; Gilsanz F
    Rev Bras Anestesiol; 2017; 67(1):89-91. PubMed ID: 25896643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Successful use of levosimendan in a patient with cardiogenic shock complicating acute myocardial infarction].
    Mustapha F; Moufida H; Nedia B; Anis L; Iheb L; Habib H
    Tunis Med; 2005 Oct; 83(10):635-7. PubMed ID: 16370217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levosimendan infusion improves haemodynamics in elderly heart failure patients undergoing urgent hip fracture repair.
    Ponschab M; Hochmair N; Ghazwinian N; Mueller T; Plöchl W
    Eur J Anaesthesiol; 2008 Aug; 25(8):627-33. PubMed ID: 18405408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levosimendan reversing low output syndrome after heart transplantation.
    Petäjä LM; Sipponen JT; Hämmäinen PJ; Eriksson HI; Salmenperä MT; Suojaranta-Ylinen RT
    Ann Thorac Surg; 2006 Oct; 82(4):1529-31. PubMed ID: 16996977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inotropic agents and vasodilator strategies for acute myocardial infarction complicated by cardiogenic shock or low cardiac output syndrome.
    Unverzagt S; Wachsmuth L; Hirsch K; Thiele H; Buerke M; Haerting J; Werdan K; Prondzinsky R
    Cochrane Database Syst Rev; 2014 Jan; (1):CD009669. PubMed ID: 24385385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of cardiogenic shock with the Ca2+ sensitizer levosimendan].
    Zobel C; Reuter H; Schwinger RH
    Med Klin (Munich); 2004 Dec; 99(12):742-6. PubMed ID: 15599685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiogenic shock after primary percutaneous coronary intervention: Effects of levosimendan compared with dobutamine on haemodynamics.
    García-González MJ; Domínguez-Rodríguez A; Ferrer-Hita JJ; Abreu-González P; Muñoz MB
    Eur J Heart Fail; 2006 Nov; 8(7):723-8. PubMed ID: 16492404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of levosimendan on the energy balance: preclinical and clinical evidence.
    Nieminen MS; Pollesello P; Vajda G; Papp Z
    J Cardiovasc Pharmacol; 2009 Apr; 53(4):302-10. PubMed ID: 19276987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of levosimendan in Takotsubo-related cardiogenic shock.
    Antonini M; Stazi GV; Cirasa MT; Garotto G; Frustaci A
    Acta Anaesthesiol Scand; 2010 Jan; 54(1):119-20. PubMed ID: 19961441
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects.
    Pathak A; Lebrin M; Vaccaro A; Senard JM; Despas F
    J Clin Pharm Ther; 2013 Oct; 38(5):341-9. PubMed ID: 23594161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction.
    Beute J
    Crit Care Med; 2009 Sep; 37(9):2678; author reply 2678-9. PubMed ID: 19687655
    [No Abstract]   [Full Text] [Related]  

  • 13. Levosimendan: beyond its simple inotropic effect in heart failure.
    Antoniades C; Tousoulis D; Koumallos N; Marinou K; Stefanadis C
    Pharmacol Ther; 2007 May; 114(2):184-97. PubMed ID: 17363065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levosimendan as rescue therapy in severe cardiogenic shock after ST-elevation myocardial infarction.
    Greif M; Zwermann L; Reithmann C; Weis M
    Acute Card Care; 2008; 10(3):185-90. PubMed ID: 18972629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
    Follath F
    Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The vasoactive-inotropic score and levosimendan: time for LVIS?
    Favia I; Vitale V; Ricci Z
    J Cardiothorac Vasc Anesth; 2013 Apr; 27(2):e15-6. PubMed ID: 23507021
    [No Abstract]   [Full Text] [Related]  

  • 17. Use of levosimendan for cardiogenic shock in a patient with the apical ballooning syndrome.
    De Santis V; Vitale D; Tritapepe L; Greco C; Pietropaoli P
    Ann Intern Med; 2008 Sep; 149(5):365-7. PubMed ID: 18765717
    [No Abstract]   [Full Text] [Related]  

  • 18. Levosimendan: current status and future prospects.
    Archan S; Toller W
    Curr Opin Anaesthesiol; 2008 Feb; 21(1):78-84. PubMed ID: 18195615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levosimendan: a new era for inodilator therapy for heart failure?
    Cleland JG; McGowan J
    Curr Opin Cardiol; 2002 May; 17(3):257-65. PubMed ID: 12015475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levosimendan neither improves nor worsens mortality in patients with cardiogenic shock due to ST-elevation myocardial infarction.
    Omerovic E; Råmunddal T; Albertsson P; Holmberg M; Hallgren P; Boren J; Grip L; Matejka G
    Vasc Health Risk Manag; 2010 Sep; 6():657-63. PubMed ID: 20859537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.